4//SEC Filing
Longpre Lara 4
Accession 0001209191-21-058606
CIK 0001759425other
Filed
Sep 30, 8:00 PM ET
Accepted
Oct 1, 8:00 PM ET
Size
6.8 KB
Accession
0001209191-21-058606
Insider Transaction Report
Form 4
Longpre Lara
Chief Development Officer
Transactions
- Award
Common Stock
2021-09-29+8,125→ 85,206 total - Sale
Common Stock
2021-10-01$19.26/sh−961$18,505→ 84,245 total
Footnotes (2)
- [F1]The shares became issuable upon the satisfaction of certain performance conditions that were established at the time of the Compensation Committee's approval of a performance-based restricted stock unit award on March 9, 2021. On September 29, 2021, the Compensation Committee certified the achievement of the performance criteria resulting in the vesting of 4,062 shares on September 29, 2021 and 4,063 shares on June 30, 2023.
- [F2]Shares sold to cover tax withholding obligations associated with the vesting of the performance-based restricted stock unit award granted to the Reporting Person on March 9, 2021.
Documents
Issuer
Mirum Pharmaceuticals, Inc.
CIK 0001759425
Entity typeother
Related Parties
1- filerCIK 0001780347
Filing Metadata
- Form type
- 4
- Filed
- Sep 30, 8:00 PM ET
- Accepted
- Oct 1, 8:00 PM ET
- Size
- 6.8 KB